Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DHR stock price vs BMY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMY's multiple
Needs BMY P/E.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
13 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BRISTOL-MYERS SQUIBB COMPANY · implied price per share
Bear
$50.67
Base
$61.69
Bull
$77.14
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
DHR vs A
ILLUMINA, INC.
DHR vs ILMN
JOHNSON & JOHNSON
DHR vs JNJ
ABBOTT LABORATORIES
DHR vs ABT
LOEWS CORP
DHR vs L
BERKSHIRE HATHAWAY INC
DHR vs BRK-B
Pfizer Inc.
DHR vs PFE
Merck & Co., Inc.
DHR vs MRK
AbbVie Inc.
DHR vs ABBV
Eli Lilly and Company
DHR vs LLY
Amgen Inc.
DHR vs AMGN
Gilead Sciences, Inc.
DHR vs GILD
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DHR can sustain materially higher growth and maintain premium margins long enough to justify a 38.6x P/E, then hold or add selectively; otherwise, the data supports trimming or avoiding DHR because its current price is far above both BMY-implied valuation and the DCF range.
DHR trades at a steep premium to BMY across valuation metrics, yet the implied price from the P/E comparison is far below the current share price. The gap is driven by DHR’s much higher multiples rather than a clear enough fundamental superiority to offset them.
Supporting Metrics
